Related Experiment Video
Updated: Feb 10, 2026

Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
Published on: May 26, 2023
Personalized medicine in pancreatic cancer: the revolution has begun
Raphaël Maréchal1,2, Francesco Puleo1,2, Anne Demols1
1Department of Gastroenterology & Gastrointestinal Cancer Unit, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070 Brussels, Belgium.
Abstract:
Pancreatic ductal adenocarcinoma carries a dismal prognosis. Both chemotherapy and targeted therapies have been disappointing when administered to unselected populations. Recently, progress has been made in our understanding of the genomic landscape of this cancer which displays remarkable heterogeneity suggesting a reorientation of management and research strategies based on molecular characterization and adapted personalized therapy. Resectable disease offers new opportunities for translational research through functional imaging response evaluation and tumor tissue acquisition before and after neoadjuvant therapy. There is urgent need for clinical trials based on molecular profiling in pancreatic ductal adenocarcinoma. In this review we discuss opportunities and limitations of these new strategies, underlining the importance of tissue acquisition and integration of molecular biomarkers in future molecularly driven clinical trials.
Insights
Pancreatic cancer (PDAC) management needs molecular insights due to its heterogeneity. Personalized therapy and molecular profiling are crucial for developing effective clinical trials and improving patient outcomes.
Area of Science:
- Oncology
- Genomics
- Translational Research
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with limited success for current chemotherapy and targeted therapies in unselected patients.
- Recent advances in understanding PDAC's genomic landscape reveal significant heterogeneity.
- This heterogeneity necessitates a shift towards molecular characterization for personalized treatment strategies.
Purpose of the Study:
- To review the opportunities and limitations of molecularly driven strategies in pancreatic cancer research and management.
- To highlight the importance of tissue acquisition and molecular biomarkers in future clinical trials.
Main Methods:
- Review of current literature on pancreatic ductal adenocarcinoma genomics and therapeutic strategies.
- Discussion of translational research opportunities in resectable PDAC using neoadjuvant therapy, functional imaging, and tissue analysis.
- Emphasis on integrating molecular profiling into clinical trial design.
Main Results:
- Current treatments for pancreatic cancer are largely ineffective in unselected populations.
- Molecular characterization of PDAC reveals substantial heterogeneity.
- Resectable disease provides a platform for translational research and evaluating treatment response.
Conclusions:
- Personalized therapy based on molecular profiling is essential for advancing pancreatic cancer treatment.
- Tissue acquisition and molecular biomarker integration are critical for developing effective, molecularly driven clinical trials.
- A reorientation of management and research strategies towards molecular characterization is urgently needed for PDAC.
More Related Videos
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Area of a Surface of Revolution
Volumes of Solids of Revolution
Centroid for the Paraboloid of Revolution
The centroid for the paraboloid of revolution is the point where all the mass of the paraboloid is concentrated. This centroid is important for engineering applications, as it determines how forces are...
Microorganisms in Medicine and Therapeutics
Personal Identity

